The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 180, 5593 -5600
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, H.
Right arrow Articles by Weissman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, H.
Right arrow Articles by Weissman, D.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HIV Envelope Suppresses CD4+ T Cell Activation Independent of T Regulatory Cells1

Haitao Hu, Kathy Fernando, Houping Ni and Drew Weissman2

Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
We previously demonstrated that HIV envelope glycoprotein (Env), delivered in the form of a vaccine and expressed by dendritic cells or 293T cells, could suppress Ag-stimulated CD4+ T cell proliferation. The mechanism remains to be identified but is dependent on CD4 and independent of coreceptor binding. Recently, CD4+ regulatory T (Treg) cells were found to inhibit protective anti-HIV CD4+ and CD8+ T cell responses. However, the role of Tregs in HIV remains highly controversial. HIV Env is a potent immune inhibitory molecule that interacts with host CD4+ cells, including Treg cells. Using an in vitro model, we investigated whether Treg cells are involved in Env-induced suppression of CD4+ T cell proliferation, and whether Env directly affects the functional activity of Treg cells. Our data shows that exposure of human CD4+ T cells to Env neither induced a higher frequency nor a more activated phenotype of Treg cells. Depletion of CD25+ Treg cells from PBMC did not overcome the Env-induced suppression of CD4+ T cell proliferation, demonstrating that CD25+FoxP3+ Treg cells are not involved in Env-induced suppression of CD4+ T cell proliferation. In addition, we extend our observation that similar to Env expressed on cells, Env present on virions also suppresses CD4+ T cell proliferation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
One of the hallmarks of HIV-associated defects in cell-mediated immunity is the progressive loss of CD4+ T cell responses, even before a significant decrease in peripheral blood CD4+ T cell numbers occurs (1). In addition, CD4+ T cell defects, when matched for disease stage, are more pronounced in the setting of high viral loads. The HIV envelope glycoprotein (Env)3 has immunosuppressive activities that can target host CD4+ cells for suppression through interaction with CD4 and/or chemokine coreceptors (2, 3, 4). Our studies have demonstrated that surface expression of Env on dendritic cells (DCs) or 293T cells (a model of vaccine expression of Env by nonlymphoid cells as would be delivered by DNA or viral vector) induces suppression of Ag-stimulated CD4+ T cell activation and proliferation but does not lead to anergy, apoptosis, or cell death. These Env exposed CD4+ T cells can phosphorylate key signaling mediators including MAPK, AKT, and STAT5a in a normal fashion but fail to fully up-regulate activation markers such as CD69, HLA-DR, and CD25 (5). Hence, the mechanism exploited by Env to suppress Ag-stimulated CD4+ T cell proliferation in this system remains to be identified. Moreover, in addition to Env expressed by cells (either infected or after Env vaccine delivery), free circulating virions can deliver Env to CD4+ T cells. Whether Env on virions induces similar suppression remains unclear.

Regulatory T (Treg) cells, a subset of CD4+ T cells, were initially thought to regulate autoimmunity. There is now a growing body of evidence suggesting that Treg cells are also actively engaged in regulating the magnitude of host T cell responses during chronic infections, including HIV (6, 7, 8). Treg cells isolated from the peripheral blood (PB) and lymphoid node (LN) of HIV infected patients have been reported to maintain a suppressive activity on HIV-specific CD4+ and CD8+ T cell responses (9, 10, 11). In studies using PB, both increased (8, 10, 12) and reduced (13, 14) frequencies of CD4+CD25+ Treg cells in HIV+ patients were reported, leading to two converse hypotheses that HIV drives expansion of Treg cells or HIV induces a selective loss of Treg cells. Subsequent studies using LN or gastrointestinal mucosal tissue demonstrated an increased frequency of suppressive Treg cells in HIV-infected patients, supporting the hypothesis that Treg cells, rather than undergoing a selective loss induced by virus, migrate from PB and accumulate at sites of viral expression, where they can exert suppression on Ag-specific T cell activation (15, 16, 17). Issues with regard to whether and how HIV regulates the frequency and function of Treg cells during infection, and how this regulation relates to HIV pathogenesis and host immunity, remain highly controversial. There is limited evidence, so far, demonstrating the direct interaction of Treg cells and HIV or its gene products. Human Treg cells isolated from healthy donors express the HIV coreceptor CCR5 and were reported to be the target of HIV infection with high susceptibility (13). In contrast, it has been demonstrated that HIV increases Treg viability through Env-CD4 interaction, resulting in accumulation of Treg cells (16).

In the present study, using an in vitro system that models the in vivo interaction between CD4+ T cells and Env, we investigated the involvement of CD25+ Treg cells in Env-induced suppression of CD4+ T cell activation and proliferation. Our data demonstrates that CD25+ Treg cells are not required for Env-induced inhibition of CD4+ T cell proliferation, and that Env does not directly activate PB Treg cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Cells and HIV-1

Human embryonic kidney 293T cells (American Type Culture Collection) were maintained in DMEM (Invitrogen Life Technologies) supplemented with 10% FCS (HyClone) and glutamine (Invitrogen Life Technologies). PBMC from HIV-negative donors were obtained through an IRB-approved protocol and maintained in complete RPMI 1640 (Invitrogen Life Technologies) containing 10% FCS and glutamine. Aldrothiol-2 (AT-2) inactivated (18) HIV-1 NL4–3 virions were obtained from University of Pennsylvania Center for AIDS Research (CFAR) virology core.

Plasmid constructs and RNA synthesis

HIV Envs encoding IIIB, YU2, and 89.6 were cloned into the RNA expression plasmid pT7TS that contains a T7 promoter, 5' and 3' UTR sequences of Xenopus β-globin, and a 30-nuc long A tail (19). Plasmids were linearized with restriction enzymes and in vitro transcribed with T7 polymerase (mMessage T7 Ultra Kits (Ambion)), extended poly-A tail was added. RNA was maintained in nuclease-free water at a concentration of 1 µg/µl and stored at –20°C.

CD25+ cell depletion and T cell proliferation assay

CD25+ cells were depleted from PBMC using magnetic beads (Dynabeads CD25; Invitrogen Life Technologies). Briefly, PBMC and magnetic beads were washed twice with PBS containing 1% FBS. Then 1 x 107 cells/ml were mixed with a 40:1 ratio of beads to CD25+ cells assuming 5% of cells expressed CD25, and rotated at 4°C for 45 min. A second round of depletion was performed with a decreased volume of beads (half of that used in the first round) to achieve near complete depletion of CD25+ cells. Whole and CD25-depleted PBMC were CFSE labeled, as described previously (5), and cultured with Env-expressing and control 293T cells in presence of TCR stimulation.

CD4+ T cell proliferation

Transcribed mRNA encoding HIV Env was complexed to lipofectin for delivery to cells as described previously (19). 293T cells seeded in 12-well plates with an approximate 90% confluence (5 x 105 cells) were transfected with Env (IIIB, YU2, and 89.6) encoding mRNA (5 µg/ml) or control poly(AC) RNA (Sigma-Aldrich), incubated for 4 h to allow protein expression, and cocultured with 2 x 106 CFSE loaded cells (PBMC or CD25-depleted PBMC) in the presence of stimulation with soluble anti-CD3 mAb (1 µg/ml; Ortho Biotech) and IL-2 (20 U/ml; AIDS Reference and Reagent Program) (20) or TSST-1 superantigen with or without soluble CD4 (sCD4) (10 µg/ml; AIDS Reference and Reagent Program) (21). Increasing or decreasing the ratio of Env-expressing 293T cells to PBMC did not affect suppression of CD4+ T cell proliferation. For exposure to free virions, 2 x 106 CFSE+ PBMC were incubated with AT-2-inactivated HIV-1 NL4–3 virions at concentrations of 1, 0.3, or 0.1 µg HIV p24 Gag equivalents/ml, which corresponds to a gp120 concentration of ~1, 0.3, and 0.1 nM, respectively (16). Four days after Env exposure, PBMC were collected, washed with PBS containing 1% FCS, and stained with anti-CD4-allophycocyanin (RPA-T4; BD Pharmingen). Cells were analyzed with a FACS-Calibur flow cytometer, and proliferation of CD4+ T cells was analyzed by CFSE dilution using Cellquest software (BD Pharmingen). A minimum of 10,000 events were analyzed. The percent of stimulated CD4+ T cells that proliferated was calculated as described (22).

Treg sorting and suppression culture

Whole PBMC or CD25-depleted PBMC were cultured with Env-expressing or control 293T cells. During Env exposure, whole PBMC were unstimulated, whereas CD25-depleted PBMC were stimulated with anti-CD3 and IL-2. A total of 48 h after Env exposure, PBMC were removed from 293T monolayer and stained with anti-CD4-FITC, anti-CD25-PE-Cy5, and anti-CD127-PE (BD PharMingen). CD4+, CD127–, CD25+ cell sorting was performed on a FACS/Aria (BDbioscience) to obtain the suppressors. A total of 2 x 105 CFSE labeled CD25-depleted autologous PBMC responders were mixed with increasing amounts of FACS sorted CD4+, CD127–, CD25+ suppressors (Suppressor to Responder ratios of 1:3 and 1:6) in the presence of stimulation with anti-CD3 and IL-2. Four days after coculture, the proliferation of responder cells was determined by flow cytometry.

Treg analyses

PBMC were exposed to Env (either on 293T- or on AT-2-treated virions) as described above. For exposure to 293T cells, PBMC were either resting or stimulated by anti-CD3 and IL-2. For incubation with AT-2 inactivated virions, resting PBMCs were used. At various time points after Env exposure (days 1, 3, and 5), PBMC were collected, washed with PBS containing 1% FCS, and stained with anti-human CD4-FITC (SK3; BD Pharmingen) and anti-CD25-PE-Cy5 (M-A251; BD Pharmingen). Cells were then washed, fixed with 2% paraformaldehyde (eBiosicence), permeabilized with PBS 1% FCS containing 0.1% saponin (eBioscience), incubated with normal rat serum at 4°C for 15 min, and stained with anti-human FoxP3-allophycocyanin (PCH101; eBioscience) on ice for 30 min according to the manufacturer’s instructions. The appropriate isotype-matched Abs were used to define background staining. Expression of CD4, CD25, and FoxP3 in cells were determined by flow cytometry. A minimum of 10,000 events were analyzed.

IL-10 and TGF-β ELISA

IL-10 and TGF-β concentrations in culture supernatants were determined by commercially available ELISA kits (BD OptEIA) according to the manufacturer’s instructions.

Statistics

Mean, SEM, and student’s t test were performed using Microsoft Excel software.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Env expressed on free virions suppresses CD4+ T cell proliferation

In HIV infection, Env present on infected cells and free virions can contact CD4+ T cells and induce dysfunction (23). We previously reported that Env expression on cells, as occurs during vaccination with encoding vectors, such as DNA or viruses, induces an inhibition to Ag-specific CD4+ T cell proliferation in a CD4-dependent manner (5). This system used human PBMC as a source of CD4+ T cells that were cultured with Env-expressing mRNA transfected 293T cells or vaccinia virus infected DC in the presence of either anti-CD3 or superantigen (TSST-1) stimulation. To test whether Env on virions is also able to induce suppression of anti-CD3 stimulated CD4+ T cell proliferation, we incubated PBMC with increasing amounts of AT-2-inactivated HIV-1 (NL4–3), which is infection deficient but retains a functional (able to bind CD4) Env, modeling the noninfectious interactions between circulating free virions and CD4 in HIV infection (16). We found that inactivated virus could inhibit anti-CD3 stimulated CD4+ T cell proliferation in a dose dependent manner, which was overcome by sCD4 (Fig. 1, A and B), similar to that observation for Env expressed on cells (Fig. 1, C and D). Similar results were observed when TSST-1 superantigen was used as a stimulus. Variability in the amount of suppression was observed for different preparations of AT-2 virus ranging from 29% (Fig. 1, A and B) to greater than 60% (data not shown). The data in Fig. 1B shows the percentage of CD4+ T cells that were stimulated to proliferate in the culture at the initiation of stimulation (22). Deceased fluorescence intensity of anti-CD4 SK3 mAb staining for virion-incubated PBMC (24) verified a functional interaction between CD4 and Env (data not shown). Interestingly, we found that proliferation of CD4-negative cells was also abrogated after incubation with 1 µg/ml virions (Fig. 1A), which could be due to impairment of CD4+ T cell helper functions by Env, leading to decreased growth cytokine production (IL-2 and others) and less activated accessory cells that, in turn, cause a decrease in Ag-stimulated CD8+ T cell proliferation.


Figure 1
View larger version (53K):
[in this window]
[in a new window]

  		FIGURE 1. HIV Env induces suppression of anti-CD3 stimulated CD4+ T cell proliferation through CD4 binding. Freshly isolated human PBMC were CFSE labeled and exposed to AT-2-treated HIV-1 virions (A and B) or Env (IIIB, 89.6, and YU2)-expressing 293T cells (C and D) in the presence or absence of sCD4 (10 µg/ml). The cultures were stimulated with anti-CD3 mAb and IL-2. Four days after Env exposure and stimulation, PBMC were stained for CD4 and the proliferation of CD4+ T cells was monitored by flow cytometry (A and C). The percent of input CD4+ T cells that proliferated (B and D) was calculated as described (22 ). Data are representative of three experiments. B, 1p = 0.05. p values calculated using 2-tailed homoscedastic student’s t test comparing AT-2 virus-treated CD4+ T cell proliferation to no virus treated. D, 1p < 0.01. p values calculated using 2-tailed homoscedastic student’s t test comparing 293T-expressed Env-treated CD4+ T cell proliferation to no Env-treated.

 
CD25+ Treg cells are not required for Env-induced suppression

We then investigated whether CD25+ Treg cells are involved in Env-induced suppression in our system. CFSE stained total or CD25-depleted PBMC were cultured with Env-expressing or control 293T cells in the presence of anti-CD3 and IL-2 stimulation. CD25 staining verified that with two rounds of magnetic bead depletion >95% of CD25+ cells were removed from PBMC (Fig. 2A). As expected, CD25-depletion significantly enhanced the proportion of proliferating CD4+ T cells in both Env-exposed (from 2.8 to 5.2%) and control cultures (from 4.6 to 10.4%) (Fig. 2, B and C). However, exposure to Env caused almost a 50% decrease in the proportion of proliferating CD4+ T cells in CD25-depleted PBMC (from 10.4 to 5.2%) (Fig. 2, B and C), suggesting that pre-existing CD25+ Treg cells were not required for Env-induced suppression of CD4+ T cell proliferation. Similar results were observed when TSST-1 superantigen was used as a stimulus.


Figure 2
View larger version (32K):
[in this window]
[in a new window]

  		FIGURE 2. CD25+ Treg cells are not required for Env-induced suppression of proliferation. CD25+ cells were depleted from human PBMC using two rounds of CD25 magnetic beads. Flow cytometric analysis demonstrated depletion of greater than 95% of CD25+ cells (A). CFSE labeled whole (top, B) or CD25-depleted (bottom, B) PBMC were exposed or not to IIIB Env-expressing 293T cells in the presence of anti-CD3 and IL-2 stimulation. CD4+ T cell proliferation 4 days after Env exposure is shown. C, The percent of input CD4+ T cells that proliferated is shown for each condition. 1p < 0.01. p values were calculated using a 2-tailed homoscedastic student’s t test comparing Env-treated CD4+ T cell proliferation to no virus-treated. Data are representative of at least four repetitions.

 
Effect of Env on frequency of CD4+, CD25+, FoxP3+ cells in PBMC

We show that CD25+ Treg cells are not required for Env to induce suppression of CD4+ T cell proliferation. One important question that remains highly controversial is whether and how HIV, or its associated gene products, regulate Treg cells. Both increased and reduced frequency of Treg cells have been reported in HIV+ patients compared with uninfected people (8, 10, 12). To test whether Env, as the major surface Ag of HIV, directly induces or activates Treg cells, we first determined and compared the percentage of CD4+, CD25+, FoxP3+ cells in both stimulated and resting human PBMC with or without exposure to Env expressed on 293T cells. Compared with resting PBMC, stimulation caused approximately a two-fold increase in the amount of CD4+, CD25+, FoxP3+ T cells in PBMC at all time points studied (Fig. 3A), which is consistent with a study demonstrating activation induced FoxP3 expression in human T cells (25). Of importance, for both resting and stimulated PBMC, Env exposure did not induce significant changes in the percentage of CD4+, CD25+, FoxP3+ T cells (Fig. 3A). Analyses of T cell proliferation in the activated cells demonstrated a significant reduction of CD4+ T cell divisions when cultured with Env mRNA transfected 293T cells, verifying Env expression on 293T cells and its inhibitory effect.


Figure 3
View larger version (49K):
[in this window]
[in a new window]

  		FIGURE 3. Effect of Env delivered by cell surface expression or on virions on FoxP3+, CD25+ Treg cells in unstimulated and stimulated PBMC. Unstimulated or anti-CD3 stimulated PBMC were analyzed by flow cytometry for CD25 and FoxP3 expression on CD4+ T cells at days 1, 3, and 5 after exposure to HIV Env expressed by 293T cells (A) or AT-2-treated virions (B). Histograms shown are gated on live CD4+ cells. Data are representative of at least four repetitions.

 
We then investigated whether Env present on free virions affected the percentage of FoxP3+ Treg cells in PBMC, as we observed inhibition of CD4+ T cell proliferation by free virions (Fig. 1, A and B). PBMC were incubated with AT-2-inactivated HIV-1 virions at 1 µg/ml p24 Gag protein equivalent. Surface and intracellular staining demonstrated no significant difference in the number of CD4+, CD25+, FoxP3+ cells between virion incubated and control PBMC at all studied time points (days 1, 3, and 5) (Fig. 3B), which is in contrast with the observation that exposure of purified CD4+ T cells to AT-2-treated HIV resulted in significantly increased FoxP3 expression at both mRNA and protein levels, resulting from Env-induced enhancement in cell viability and consequent accumulation of FoxP3+ cells (16). Taken together, our data suggested that neither Env delivered on cells as would be found during infection or after encoding vector delivery as part of a vaccine nor Env present on free virions could directly induce or activate T regulatory cells in resting or stimulated PBMC.

IL-10 and TGF-β production in Env-exposed PBMC

Immune suppression mediated by Treg cells can occur through either cell contact or suppressive cytokines, particularly IL-10 and TGF-β (26, 27, 28). To test whether Env exposure, rather than inducing an increased number of FoxP3+ cells, stimulates an enhanced production of IL-10 and/or TGF-β by Tregs, supernatants of cultures with and without Env exposure were collected at various time points (days 1, 3, and 5) after initiation of coculture, followed by quantitation of IL-10 and TGF-β by ELISA. TGF-β was undetectable at any of the studied time points in both Env exposed and control supernatants (data not shown). Significant amounts of IL-10 were produced and accumulated in the supernatants starting at 12 h after stimulation. However, no difference was observed in the amount of IL-10 production between Env-exposed and control cultures (Fig. 4). Considered together, these data suggest that Env does not induce a more activated phenotype of Treg cells leading to increased suppressive cytokine production.


Figure 4
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 4. Effect of Env exposure on IL-10 production. 293T cells expressing IIIB Env or control transfected were cultured with PBMC in the presence or absence of anti-CD3 and IL-2 stimulation. Supernatants were collected at the indicated time points, and supernatant associated IL-10 was determined by ELISA. Data are representative of at least five experiments. Error bars are the SEM for triplicate measurements.

 
Env does not enhance the suppressive activity of CD4+, CD25+, CD127– T cells

We demonstrate that Env induces neither an increased number of CD4+, D25+, FoxP3+ cells nor enhanced IL-10 and TGF-β production in PBMC, and their depletion does not negate Envs ability to suppress CD4+ T cell proliferation. To test whether Env activates Treg cells, resulting in an enhanced suppressive activity independent of IL-10 or TGF-β, an in vitro suppression assay was developed in which Treg cells isolated from Env-exposed and control PBMC were cultured with autologous responder cells in the presence of anti-CD3 stimulation (29). The suppressive activity of Treg cells, on a per-cell basis, was evaluated by their capacity to inhibit anti-CD3 stimulated responder cell division. In addition to CD25, CD127, a subunit of the IL-7R, has also been shown to be a useful cell surface marker for defining Tregs (30, 31). We sorted Tregs from control RNA or Env RNA-transfected 293T cell exposed PBMC based on CD4+, CD25+, and CD127– expression. Greater than 90% of the sorted cells expressed FoxP3 (Fig. 5A).


Figure 5
View larger version (35K):
[in this window]
[in a new window]

  		FIGURE 5. Endogenously present or activation induced (plus FoxP3+,CD25–) FoxP3+ Treg cell suppressive activity is not modulated by Env. A, Isolation of FoxP3+ Treg cells from PBMC using CD4, CD25, and CD127. CD4+ live lymphocyte sized cells (gate in top panel of A) were sorted for high CD25 and no CD127 expression (gate in middle panel of A). The sorted cells were stained for FoxP3 (A, lower panel) and demonstrated greater than 90% positivity. B, As a source of suppressors, PBMC were cultured with Env expressing or control 293T cells, followed by isolation of CD4+, CD25+, CD127– T cells by flow cytometric sorting (detailed in A) 48 h after Env exposure. CFSE-labeled responder cells (autologous PBMC depleted of CD25+ cells) were cocultured with graded numbers of sorted CD4+, CD25+, CD127– suppressor cells in the presence of anti-CD3 and IL-2 stimulation. CFSE intensity of responder cells with CD4 staining was monitored by flow cytometry at day 4 to quantify responder cell proliferation. C, Percent of input CD4+ T cells that proliferated was calculated for each condition. 1p < 0.007. p values calculated using 2-tailed homoscedastic student’s t test comparing 293T Env-treated CD4+ T cell proliferation to no Env-treated. D, As a source of suppressors, CD25-depleted PBMC were cultured with Env expressing or control 293T cells in the presence of anti-CD3 and IL-2 stimulation, followed by isolation of CD4+, CD25+, CD127– T cells 48 h after stimulation, as described in A. CFSE-labeled responder cells (autologous PBMC depleted of CD25+ cells) were cocultured with graded numbers of sorted CD4+, CD25+, CD127– suppressor cells in the presence of anti-CD3 and IL-2 stimulation. CFSE intensity of responder cells with CD4 staining was monitored by flow cytometry at day 4 to quantify responder cell proliferation. E, Percent of input CD4+ T cells that proliferated was calculated for each condition. 1p < 0.009. p values calculated using 2-tailed homoscedastic student’s t test comparing 293T-Env-treated CD4+ T cell proliferation to no Env-treated. Data are representative of at least three repetitions.

 
We observed a population of FoxP3+ cells that did not express CD25 after CD25-depletion of PBMC that accounted for ~40% of the FoxP3+, CD4+ cells. In addition to natively expressed FoxP3, an additional population of FoxP3+ cells also appears after activation. These cells are derived from FoxP3–, CD4+ cells and their ability to suppress immune responses is controversial (25). We attempted to use the above sorting strategy to isolate FoxP3+ Treg cells after Env exposure and anti-CD3 stimulation. It should be noted that activation induces up-regulation of CD25 as well as down-regulation of CD127 on non-Treg CD4+ T cells, making the isolation of FoxP3+ cells less accurate. However, approximately 30–50% of the sorted cells from stimulated PBMCs expressed FoxP3.

Sorted CD4+, CD25+, CD127– cells (90% FoxP3+) inhibited responder CD4+ T cell proliferation in a dose-dependent manner, where in the absence of added Tregs, 56.2% of the input cells proliferated after stimulation and the addition of one Treg per three responder cells (CD25-depleted PBMC) decreased the percent of proliferating CD4+ T cells to 29.1 and at one Treg per 6 responder cells, 46.4% of the CD4+ T cells proliferated (Fig. 5, B and C). However, Env-exposed and control CD4+, CD25+, CD127– T cells were equally suppressive, because no significant difference in the proportion of dividing responder cells was found between them (Fig. 5, B and C).

We then determined whether Env induces a more suppressive activity of activation induced FoxP3+ cells, which also contained the FoxP3+, CD25– population, by sorting CD4+, CD25+, CD127– T cells from PBMC, which were first depleted of CD25+ cells, then cocultured with 293T cells (with and without Env), and finally activated by anti-CD3. Activation induced CD4+, CD25+, CD127– T cells (~30–50% FoxP3+), although slightly less suppressive than natural FoxP3+ cells isolated from unstimulated PBMC, inhibited CD4+ T cell proliferation in a dose-dependent manner (Fig. 5, D and E). Of importance, no difference in suppressive ability between Env exposed and control activation-induced Treg cells was observed (Fig. 5, D and E). Taken together, these data indicate that Env exposure does not enhance the functional suppressive activity of either pre-existing Treg or activation induced FoxP3+ cells.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
HIV envelope is a potent immune inhibitory molecule that suppresses the function of CD4+ T cells (2, 3, 4). Accumulating studies have implicated the involvement of CD25+ Treg cells in the inhibition of HIV-specific CD4+ and CD8+ T cell responses during HIV infection (8, 9, 10, 11, 15, 16, 17, 32). The present study was designed to address three questions: 1) whether HIV virion expressed Env, like that expressed on the cell surface during infection or vaccination, induces inhibition of CD4+ T cell proliferation; 2) whether Treg cells are responsible, at least in part, for this Env induced suppression of proliferation; and 3) whether Env is able to directly induce, or activate, Treg cells. The answers to these questions are critical in determining whether the frequency and function of Treg cells are regulated through direct interaction with virus and how this regulation of Treg cells relates to dysfunction of T cell immunity in HIV infection. In this study, we demonstrate that Env expressed on either virions or cells induces suppression of CD4+ T cell activation, and that Env does not induce or activate Treg cells as a mediator for this inhibition.

Cell membrane-bound HIV Env (as occurs with infection or after certain types of Env vaccine delivery) has been demonstrated to suppress polyclonal TCR (anti-CD3)- or Ag (TSST-1)-stimulated CD4+ T cell activation featuring a lack of proliferation (5). In HIV infection, in addition to infected cells, circulating free virions also bear functional trimeric Env. Although protease-defective gp120-containing HIV-1 particles were reported to induce apoptosis in human PB T cells, whether such virions use Env, like its counterpart expressed on cells, to induce inhibition to CD4+ T cell proliferation remains unclear (33). Using AT-2 inactivated HIV-1 viral particles that are noninfectious but maintain functional Env (16, 34), we demonstrate that Env on HIV virions inhibits CD4+ T cell proliferation through gp120-CD4 signaling.

HIV impairs host CD4+ T cell immunity through multiple mechanisms. Although the involvement of Treg cells in suppressing anti-HIV-specific T cell responses has been documented in a growing body of literature (8, 9, 10, 11, 15, 16, 17, 32), there is still no study answering whether HIV inhibits host CD4+ T cell activation through the direct induction or activation of Treg cells. An interaction between Treg cells and HIV through gp120-CD4 signaling has been proposed (16), which provides a basis for our in vitro system where human PBMC, as source of CD4+ T cells, were exposed to Env expressing 293T cells or AT-2-inactivated virions, modeling the in vivo interaction between Env and CD4+ effector as well as CD4+ Treg cells, during an immune response. In this study, we show that depletion of pre-existing CD4+, CD25+ Treg cells from PBMC increases the proliferation of polyclonal TCR- and Ag-stimulated CD4+ T cells, which is consistent with observations in HIV-infected patients that virus exposed Treg cells maintain suppressive activity. However, Env-induced inhibition remained in the absence of CD25+ Treg cells, strongly suggesting that Treg cells are not functionally involved in Env induced suppression. This result implies that the suppressive effect of Treg cells on anti-HIV T cell responses, which has been observed in HIV-infected patients, may be a general feature of Treg cells (35, 36).

The regulation of Treg cells in HIV remains highly controversial. Studies using PB reported increased (8, 10, 12) as well as reduced (13, 14) numbers of Treg cells in HIV infection. In contrast, later studies using LN or gastrointestinal mucosa of infected patients demonstrated up-regulation of FoxP3 and other markers of Treg cells, supporting Treg accumulation in the tissue at sites of viral replication (15, 16, 17, 32). Factors including markers used to identify Treg cells, disease stage in selected patients, and Highly Active Antiretroviral Therapy treatment might contribute to the various findings from different studies. Our results demonstrate that regardless of the form of Env delivery (Env-expressing cells as would be observed during infection or after encoding vaccine delivery or free virions) and stimulation status of T cells, the percentage of FoxP3+, CD25+, CD4+ T cells was not affected by Env, which is in contrast to the observation that an increase in FoxP3+ cells was detected in CD4+ T cells after exposure to AT-2-inactivated virions, resulting from Env induced enhancement in Treg cell viability (16). The difference in cells used (PBMC vs purified CD4+ T cells) could have contributed to the different results in these two studies. The purification of CD4+ T cells could have increased their level of apoptosis, which was blunted by Env acting on Tregs or increased by Env acting on non-Treg CD4+ T cells. We observed a low level of apoptosis in our unstimulated PBMC with no difference between Env exposed and control (data not shown). Although, if this were the case, we would have expected to see a difference after anti-CD3 stimulation (Fig. 3A), which increases apoptosis.

It has been reported that, unlike murine Foxp3– T cells, a subset of human FoxP3– T cells could be induced to transiently express FoxP3 upon activation (25, 37). In agreement with these studies, we found that anti-CD3 stimulation induced increased FoxP3 expression in CD4+ T cells, peaking at ~48 h after activation. Furthermore, we measured FoxP3 expression in CD25-depleted PBMC, and found, first, that a population of CD25–, FoxP3+ cells were present and they accounted for ~40% of the total FoxP3+ cells in PBMC and, second, that activation induced FoxP3 expression, which is in agreement with a published report (38). These activation induced FoxP3+, CD4+ T cells and CD25–, FoxP3+, CD4+ T cells together have suppressive activity on T cell proliferation, but this activity was not modulated by Env exposure.

One of the functional characteristics of Treg cells are their capacity to suppress Ag-specific CD4+ and CD8+ T cell proliferation in a dose-dependent manner (35, 36, 39). Since FoxP3 is expressed intracellulary, several surface Ags in addition to CD25 have been identified as alternative markers for isolation of Treg cells, one of which is CD127, a subunit of the IL-7R (31). Analysis of sorted CD4+, CD25+, CD127– T cells, which contained 90% FoxP3+ cells, demonstrated that Env exposure did not alter the suppressive activity of PB Treg cells, which is consistent with a previous finding that Treg cells exposed to AT-2-treated HIV virions are equally suppressive compared with untreated Treg cells (16).

In summary, our data demonstrates that HIV Env neither induced nor activated Treg cells, and that CD25+ Treg cells are not responsible for Env-induced suppression of CD4+ T cell proliferation. Our findings do not demonstrate that HIV does not regulate Treg number or function, only that Env binding does not, in model in vitro assays. Treg cells could still be depleted by direct infection or bystander effects or their number increased by other gene products or downstream effects of infection, such as chronic immune stimulation. Further work is needed to elucidate the in vivo regulation of Treg cells and their physiological relevance in the context of HIV infection and vaccination.


   Acknowledgments
 
The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health: Human rIL-2 from Dr. Maurice Gately, Hoffmann-La Roche Inc; sCD4–183 from Pharmacia.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grants R01 AI50484. Back

2 Address correspondence and reprint requests to Dr. Drew Weissman, 522B Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104. E-mail address: dreww{at}mail.med.upenn.edu Back

3 Abbreviations used in this paper: Env, HIV envelope glycoprotein; DC, dendritic cell; Treg, regulatory T; PB, peripheral blood; LN, lumph node; AT-2, Aldrothiol-2; s, soluble. Back

Received for publication December 11, 2007. Accepted for publication February 8, 2008.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Miedema, F., A. J. C. Petit, F. G. Terpstra, J. Schattenkerk, F. Dewolf, B. J. M. Al, M. Roos, J. M. A. Lange, S. A. Danner, J. Goudsmit, P. T. A. Schellekens. 1988. Immunological abnormalities in human immunodeficiency virus (Hiv)-infected asymptomatic homosexual men: Hiv affects the immune-system before Cd4+ T-helper cell depletion occurs. J. Clin. Invest. 82: 1908-1914. [Medline]
  2. McMichael, A. J., S. L. Rowland-Jones. 2001. Cellular immune responses to HIV. Nature 410: 980-987. [Medline]
  3. Arthos, J., C. Cicala, S. M. Selig, A. A. White, H. M. Ravindranath, D. Van Ryk, T. D. Steenbeke, E. Machado, P. Khazanie, M. S. Hanback, et al 2002. The role of the CD4 receptor versus HIV coreceptors in envelope-mediated apoptosis in peripheral blood mononuclear cells. Virology 292: 98-106. [Medline]
  4. Holm, G. H., D. Gabuzda. 2005. Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J. Virol. 79: 6299-6311. [Abstract/Free Full Text]
  5. Fernando, K., H. T. Hu, H. P. Ni, J. A. Hoxie, D. Weissman. 2007. Vaccine-delivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses. Blood 109: 2538-2544. [Abstract/Free Full Text]
  6. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507. [Medline]
  7. Taylor, J. J., M. Mohrs, E. J. Pearce. 2006. Regulatory T cell responses develop in parallel to Th responses and control the magnitude and phenotype of the Th effector population. J. Immunol. 176: 5839-5847. [Abstract/Free Full Text]
  8. Aandahl, E. M., J. Michaelsson, W. J. Moretto, F. A. Hecht, D. F. Nixon. 2004. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol. 78: 2454-2459. [Abstract/Free Full Text]
  9. Kinter, A. L., M. Hennessey, A. Bell, S. Kern, Y. Lin, M. Daucher, M. Planta, M. McGlaughlin, R. Jackson, S. E. Ziegler, A. S. Fauci. 2004. CD25+ CD4+ regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4+ and CD8+ HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J. Exp. Med. 200: 331-343. [Abstract/Free Full Text]
  10. Weiss, L., V. Donkova-Petrini, L. Caccavelli, M. Balbo, C. Carbonneil, Y. Levy. 2004. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 104: 3249-3256. [Abstract/Free Full Text]
  11. Kinter, A., J. McNally, L. Riggin, R. Jackson, G. Roby, A. S. Fauci. 2007. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc. Nat. Acad. Sci. USA 104: 3390-3395. [Abstract/Free Full Text]
  12. Tsunemi, S., T. Iwasaki, T. Imado, S. Higasa, E. Kakishita, T. Shirasaka, H. Sano. 2005. Relationship of CD4+CD25+regulatory T cells to immune status in HIV-infected patients. AIDS 19: 879-886. [Medline]
  13. Oswald-Richter, K., S. M. Grill, N. Shariat, M. Leelawong, M. S. Sundrud, D. W. Haas, D. Unutmaz. 2004. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2: 955-966.
  14. Eggena, M. P., B. Barugahare, N. Jones, M. Okello, S. Mutalya, C. Kityo, P. Mugyenyi, H. Cao. 2005. Depletion of regulatory T cells in HIV infection is associated with immune activation. J. Immunol. 174: 4407-4414. [Abstract/Free Full Text]
  15. Apoil, P. A., B. Puissant, F. Roubinet, M. Abbal, P. Massip, A. Blancher. 2005. FOXP3 mRNA levels are decreased in peripheral blood CD4+ lymphocytes from HIV-positive patients. J. Aquired Immune Defic. Syndr. 39: 381-385.
  16. Nilsson, J., A. Boasso, P. A. Velilla, R. Zhang, M. Vaccari, G. Franchini, G. M. Shearer, J. Andersson, C. Chougnet. 2006. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 108: 3808-3817. [Abstract/Free Full Text]
  17. Epple, H. J., C. Loddenkemper, D. Kunkel, H. Troger, J. Maul, V. Moos, E. Berg, R. Ullrich, J. D. Schulzke, H. Stein, et al 2006. Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and nonnalize after suppressive HAART. Blood 108: 3072-3078. [Abstract/Free Full Text]
  18. Rossio, J. L., M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess, Jr, G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, et al 1998. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72: 7992-8001. [Abstract/Free Full Text]
  19. Kariko, K., A. Kuo, E. S. Barnathan. 1999. Overexpression of urokinase receptor in mammalian cells following administration of the in vitro transcribed encoding mRNA. Gene Ther. 6: 1092-1100. [Medline]
  20. Lahm, H. W., S. Stein. 1985. Characterization of recombinant human interleukin-2 with micromethods. J. Chromatogr. 326: 357-361. [Medline]
  21. Garlick, R. L., R. J. Kirschner, F. M. Eckenrode, W. G. Tarpley, C. S. C. Tomich. 1990. Escherichia-coli expression, purification, and biological-activity of a truncated soluble CD4. AIDS Res. Hum. Retroviruses 6: 465-479. [Medline]
  22. Wells, A. D., H. Gudmundsdottir, L. A. Turka. 1997. Following the fate of individual T cells throughout activation and clonal expansion: signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J. Clin. Invest. 100: 3173-3183. [Medline]
  23. Finkel, T. H., G. Tudorwilliams, N. K. Banda, M. F. Cotton, T. Curiel, C. Monks, T. W. Baba, R. M. Ruprecht, A. Kupfer. 1995. Apoptosis occurs predominantly in bystander cells and not in productively infected-cells of HIV-infected and SIV-infected lymph-nodes. Nat. Med. 1: 129-134. [Medline]
  24. Benkirane, M., M. Hirn, D. Carriere, C. Devaux. 1995. Functional epitope analysis of the human Cd4 molecule: antibodies that inhibit Human-Immunodeficiency-Virus type-1 gene-expression bind to the immunoglobulin Cdr3-like region of Cd4. J. Virol. 69: 6898-6903. [Abstract]
  25. Gavin, M. A., T. R. Torgerson, E. Houston, P. deRoos, W. Y. Ho, A. Stray-Pedersen, E. L. Ocheltree, P. D. Greenberg, H. D. Ochs, A. Y. Rudensky. 2006. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 103: 6659-6664. [Abstract/Free Full Text]
  26. Annacker, O., R. Pimenta-Araujo, O. Burlen-Defranoux, T. C. Barbosa, A. Cumano, A. Bandeira. 2001. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 166: 3008-3018. [Abstract/Free Full Text]
  27. Weiner, H. L.. 2001. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-β-secreting regulatory cells. Microbes Infect. 3: 947-954. [Medline]
  28. Belghith, M., J. A. Bluestone, S. Barriot, J. Megret, J.-F. Bach, L. Chatenoud. 2003. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9: 1202-1208. [Medline]
  29. Kataoka, H., S. Takahashi, K. Takase, S. Yamasaki, T. Yokosuka, T. Koike, T. Saito. 2005. CD25+CD4+ regulatory T cells exert in vitro suppressive activity independent of CTLA-4. Int. Immunol. 17: 421-427. [Abstract/Free Full Text]
  30. Caton, A. J., C. Cozzo, J. Larkin, III, M. A. Lerman, A. Boesteanu, M. S. Jordan. 2004. CD4+ CD25+ regulatory T cell selection. Ann. NY Acad. Sci. 1029: 101-114. [Medline]
  31. Liu, W. H., A. L. Putnam, Z. Xu-Yu, G. L. Szot, M. R. Lee, S. Zhu, P. A. Gottlieb, P. Kapranov, T. R. Gingeras, B. Fazekas de St. Groth, et al 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203: 1701-1711. [Abstract/Free Full Text]
  32. Andersson, J., A. Boasso, J. Nilsson, R. Zhang, N. J. Shire, S. Lindback, G. M. Shearer, C. A. Chougnet. 2005. Cutting edge: the prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J. Immunol. 174: 3143-3147. [Abstract/Free Full Text]
  33. Kameoka, M., T. Kimura, Y. Zheng, S. Suzuki, K. Fujinaga, R. Luftig, K. Ikuta. 1997. Protease-defective, gp120-containing human immunodeficiency virus type 1 particles induce apoptosis more efficiently than does wild-type virus or recombinant gp120 protein in healthy donor-derived peripheral blood T cells. J. Clin. Microbiol. 35: 41-47. [Abstract]
  34. Rossio, J. L., M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess, G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, Q. Sattentau, et al 1998. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72: 7992-8001. [Abstract/Free Full Text]
  35. Shevach, E. M.. 2001. Certified professionals: CD4+CD25+ suppressor T cells. J. Exp. Med. 193: 41F-46F. [Free Full Text]
  36. Read, S., F. Powrie. 2001. CD4+ regulatory T cells. Curr. Opin. Immunol. 13: 644-649. [Medline]
  37. Mantel, P.-Y., N. Ouaked, B. Ruckert, C. Karagiannidis, R. Welz, K. Blaser, C. B. Schmidt-Weber. 2006. Molecular mechanisms underlying FOXP3 induction in human T cells. J. Immunol. 176: 3593-3602. [Abstract/Free Full Text]
  38. Fantini, M. C., C. Becker, G. Monteleone, F. Pallone, P. R. Galle, M. F. Neurath. 2004. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25– T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172: 5149-5153. [Abstract/Free Full Text]
  39. Maloy, K. J., F. Powrie. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2: 816-822. [Medline]



This article has been cited by other articles:


Home page
 BloodHome page
C. Becker, C. Taube, T. Bopp, C. Becker, K. Michel, J. Kubach, S. Reuter, N. Dehzad, M. F. Neurath, K. Reifenberg, et al.
Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells
Blood, August 6, 2009; 114(6): 1263 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. M. Nyakeriga, C. J. Fichtenbaum, J. Goebel, S. A. Nicolaou, L. Conforti, and C. A. Chougnet
Engagement of the CD4 Receptor Affects the Redistribution of Lck to the Immunological Synapse in Primary T Cells: Implications for T-Cell Activation during Human Immunodeficiency Virus Type 1 Infection
J. Virol., February 1, 2009; 83(3): 1193 - 1200.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, H.
Right arrow Articles by Weissman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, H.
Right arrow Articles by Weissman, D.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS